The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
Over the past few months, Apollo Hospitals has entered into MoUs with multiple national and international air ambulance service providers
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
The new assay consolidates screening for four major viral threats into a single workflow
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Subscribe To Our Newsletter & Stay Updated
